Citadel Advisors’s Pulmonx LUNG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,600
Closed -$17.5K 13989
2025
Q1
$17.5K Buy
2,600
+2,100
+420% +$14.9K ﹤0.01% 13238
2024
Q4
$3.4K Buy
500
+200
+67% +$1.32K ﹤0.01% 13998
2024
Q3
$2.49K Sell
300
-100
-25% -$724 ﹤0.01% 13744
2024
Q2
$2.54K Sell
400
-800
-67% -$6.15K ﹤0.01% 13674
2024
Q1
$11.1K Sell
1,200
-12,000
-91% -$141K ﹤0.01% 13428
2023
Q4
$168K Sell
13,200
-3,300
-20% -$34.4K ﹤0.01% 10215
2023
Q3
$170K Sell
16,500
-7,100
-30% -$82.2K ﹤0.01% 10159
2023
Q2
$309K Sell
23,600
-19,000
-45% -$232K ﹤0.01% 8982
2023
Q1
$476K Buy
42,600
+41,200
+2,943% +$407K ﹤0.01% 8422
2022
Q4
$11.8K Buy
+1,400
New +$13.3K ﹤0.01% 13552
2022
Q1
Sell
-12,800
Closed -$411K 14174
2021
Q4
$411K Sell
12,800
-2,400
-16% -$87.7K ﹤0.01% 10148
2021
Q3
$547K Buy
+15,200
New +$598K ﹤0.01% 9641
2021
Q2
Sell
-18,100
Closed -$828K 14086
2021
Q1
$828K Buy
+18,100
New +$1.04M ﹤0.01% 8567

Other funds holding LUNG

Citadel Advisors's LUNG Position: Q1 2026 in Review

Citadel Advisors increased its Pulmonx (LUNG) stake by 26% in Q1 2026, buying an estimated $19.4K and bringing the position to 57,009 shares worth $73.5K. The position accounts for ﹤0.01% of the portfolio, ranked #12223.

Citadel Advisors first reported a position in LUNG in Q4 2020 and has held it in 22 quarters since. The position peaked at $16M in Q3 2021. 113 funds tracked by Wall St. Rank hold LUNG as of Q1 2026.

  • Citadel Advisors held 57,009 shares of Pulmonx worth $73.5K as of Q1 2026.
  • Citadel Advisors bought 11,752 Pulmonx shares in Q1 2026, an estimated $19.4K.
  • Pulmonx made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12223 holding.
  • Citadel Advisors first reported a position in Pulmonx in Q4 2020 and has held it in 22 quarters since.
  • Citadel Advisors's Pulmonx position peaked at $16M in Q3 2021.
  • 113 funds tracked by Wall St. Rank held Pulmonx as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.